Articles From: Aegion Corporation to Present at the Jefferies 2014 Global Industrials Conference to AeroCentury Corp. Announces Aircraft Purchase


2014/8/8
Aegion Corporation (Nasdaq Global Select Market: AEGN) today announced that its Interim Chief Executive Officer, Charles R.
Sign-up for Aegion Corporation to Present at the Jefferies 2014 Global Industrials Conference investment picks
2014/7/29
Aegion Corporation (Nasdaq Global Select Market: AEGN) today reported financial results for the second quarter and first six months of 2014.
Sign-up for Aegion Reports 2014 Second Quarter Financial Results investment picks
2014/7/18
THE HAGUE, Netherlands , July 18, 2014 /PRNewswire/ -- Aegon has completed the program announced on June 17, 2014 to neutralize the dilutive effect of the 2013 final dividend paid in shares.
Sign-up for Aegon completes neutralization of stock dividend dilution investment picks
2014/8/14
THE HAGUE, The Netherlands , August 14, 2014 /PRNewswire/ -- Revenue-generating investments exceed EUR 500 billion for the first time Solid business growth driving higher underlying earnings before tax Underlying earnings up 7% to EUR 514 million , driven by growth, improved operational performance and higher equity markets; partly offset by unfavorable mortality experience and exchange rate movements Fair value items loss of EUR 263 million , mainly due to hedging programs and model updates Net income up 43% to EUR 343 million , resulting mainly from higher realized gains Return on equity increases to 8.8%, or 9.6% excluding capital allocated to run-off businesses Profitable sales growth generated by expanding distribution and product innovation Gross deposits up 3% to EUR 13.0 billion , driven by pensions and variable annuities in US; record net deposits of
Sign-up for Aegon Delivers Strong Q2 2014 Results investment picks
2014/9/17
THE HAGUE, the Netherlands , September 17, 2014 /PRNewswire/ -- Shareholders were given the opportunity to choose between receiving the interim dividend of EUR 0.11 per common share in cash or in stock.
Sign-up for Aegon Determines Stock Fraction Interim Dividend and Announces to Repurchase Shares to Neutralize Stock Dividend investment picks
FREMONT, Calif., Sept.
Sign-up for Aehr Test Systems Announces ABTS(TM) System Follow-On Order From Leading IC Manufacturer investment picks
FREMONT, Calif., Sept.
Sign-up for Aehr Test Systems Reports First Quarter Fiscal 2015 Financial Results investment picks
FREMONT, Calif., July 17, 2014 (GLOBE NEWSWIRE) -- Aehr Test Systems (Nasdaq:AEHR) , a worldwide supplier of semiconductor test and burn-in equipment, today announced financial results for the fiscal 2014 fourth quarter and full year ended May 31, 2014.
Sign-up for Aehr Test Systems Reports Fourth Quarter Fiscal 2014 Financial Results investment picks
FREMONT, Calif., Sept.
Sign-up for Aehr Test Systems to Announce First Quarter Fiscal 2015 Financial Results on September 30, 2014 investment picks
FREMONT, Calif., June 26, 2014 (GLOBE NEWSWIRE) -- Aehr Test Systems (Nasdaq:AEHR) , a worldwide supplier of semiconductor test and burn-in equipment, today announced that it will report financial results for its fiscal 2014 fourth quarter ended May 31, 2014 on Thursday, July 17, 2014 following the close of the market.
Sign-up for Aehr Test Systems to Announce Fourth Quarter Fiscal 2014 Financial Results on July 17, 2014 investment picks
CUPERTINO, Calif., July 23, 2014 (GLOBE NEWSWIRE) -- Aemetis, Inc. (Nasdaq:AMTX) today announced that the company received a $3 million matching grant award from the California Energy Commission (CEC) Alternative and Renewable Fuel and Vehicle Technology Program (ARFVTP). This award comes as a result of the Company's "Low-Carbon Sorghum Ethanol Project" application to the "Pilot-Scale and Commercial-Scale Advanced Biofuels Production Facilities" grant solicitation (PON-13-609) released by the CEC earlier this year.
Sign-up for Aemetis Announces $3 Million CEC Grant Award investment picks
COLUMBUS, Ohio , Aug.
Sign-up for AEP Chief Financial Officer To Address Investors At Barclays Conference investment picks
COLUMBUS , July 28, 2014 /PRNewswire/ -- AEP Energy today began installation of a 101-kilowatt (kW) solar array on the roof of The Ohio State University's Student Life Recreation and Physical Activities Center (RPAC). AEP Energy will fund, build, own and operate the approximately 10,000-square-foot array, made up of 367 solar panels arranged in a configuration similar to the "Block O." Installation is expected to be completed in approximately eight weeks.
Sign-up for AEP Energy Installing Solar Array At Ohio State investment picks
2014/9/9
MONTVALE, N.J. , Sept.
Sign-up for AEP Industries Inc. Reports Fiscal 2014 Third Quarter And Year-To-Date Results investment picks
MONTVALE, N.J. , Sept.
Sign-up for AEP Industries Inc. Schedules Conference Call To Discuss Third Quarter 2014 Financial Results investment picks
COLUMBUS, Ohio , Aug.
Sign-up for AEP Names Reis Vice President, Audit Services investment picks
Filing maintains grid reliability while protecting customers against price volatility GAHANNA, Ohio , Oct.
Sign-up for AEP Ohio Files Expanded Purchase Power Agreement investment picks
-- Second-quarter 2014 GAAP and operating earnings $0.80 per share --
Sign-up for AEP Reports 16 Percent Increase in 2014 Second-Quarter GAAP Earnings Per Share; 10 Percent Increase in 2014 Second-Quarter Operating Earnings Per Share investment picks
COLUMBUS, Ohio , July 17, 2014 /PRNewswire/ -- American Electric Power (NYSE: AEP) has scheduled a quarterly earnings conference call with financial analysts for 9 a.m. EDT Friday, July 25 .
Sign-up for AEP Schedules Live Webcast Of Quarterly Earnings Call investment picks
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, announced today that it has received a $125 million financing commitment from Deerfield Management Company L.P. (“Deerfield”), a current Aerie shareholder.
Sign-up for Aerie Announces $125 Million Convertible Notes investment picks
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, announced today that it has closed its $125 million financing with Deerfield Management Company L.P. (“Deerfield”), a current Aerie shareholder.
Sign-up for Aerie Announces Closing of $125 Million Convertible Notes Financing investment picks
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, announced today that Benjamin F.
Sign-up for Aerie Pharmaceuticals Elects Benjamin F. McGraw, III to Its Board of Directors investment picks
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that on August 29, dosing commenced of the first patients enrolled in the Company’s Phase 3 registration trial in Canada of Rhopressa TM , a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Sign-up for Aerie Pharmaceuticals Inc. Initiates Phase 3 Safety-Only Registration Trial in Canada of RhopressaTM in Patients with Glaucoma investment picks
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that on July 11, dosing commenced of the first patients enrolled in the Company’s Phase 3 registration clinical trials of Rhopressa TM , a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Sign-up for Aerie Pharmaceuticals Initiates Phase 3 Registration Trials of RhopressaTM, Novel Triple-Action Product to Lower Intraocular Pressure in Patients with Glaucoma investment picks
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today reported financial results for second quarter 2014 and provided an update on the Company’s business highlights.
Sign-up for Aerie Pharmaceuticals Reports Second Quarter 2014 Financial Results and Provides Business and Product Development Update investment picks
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) announced today that its second quarter 2014 financial results will be released after the market closes on Wednesday, August 6, 2014.
Sign-up for Aerie Pharmaceuticals to Announce Second Quarter 2014 Financial Results and Host Conference Call on Wednesday, August 6, 2014 investment picks
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) today announced that the Company will host a live webcast in conjunction with its Investor Day on Wednesday, September 10, 2014 at 12:00p.m. ET in New York, NY.
Sign-up for Aerie Pharmaceuticals to Host Investor Day on September 10, 2014 investment picks
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) today announced that Vicente Anido, Jr., Ph.D., chairman and chief executive officer will present at the Canaccord Genuity 34th Annual Growth Conference on Wednesday, August 13, 2014 at 11:30a.m. Eastern Time in Boston, MA.
Sign-up for Aerie Pharmaceuticals to Present at the Canaccord Genuity 34th Annual Growth Conference investment picks
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that it has received a No Objection Letter (“NOL”) from Health Canada to conduct a Phase 3 registration trial of Rhopressa TM , a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension in Canada.
Sign-up for Aerie Pharmaceuticals, Inc. Receives Health Canada “No Objection Letter” to Commence Phase 3 Registration Trial of RhopressaTM in Patients with Glaucoma in Canada investment picks
2014/10/2
BURLINGAME, Calif.
Sign-up for AeroCentury Corp. Announces Aircraft Purchase investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Aegion Corporation to Present at the Jefferies 2014 Global Industrials Conference to AeroCentury Corp. Announces Aircraft Purchase
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices